On August 7, Guangdong HEC Pharmaceutical Co., Ltd. (hereinafter referred to as " HEC Pharma ") was listed on the Main Board of the Hong Kong Stock Exchange Limited (hereinafter referred to as "HKEX"). As the first H-share merger and privatization plus introduction case, HEC Pharma merged its Hong Kong-listed subsidiary Yichang HEC Pharmaceutical with the acquisition ofChangjiang Pharmaceutical Co., Ltd. has been fully listed. This is not only a milestone in the development history of this company that has been deeply engaged in innovation for 20 years, but also marks the beginning of the development of China's innovative drugs.Asset SecuritiesThis is a breakthrough in the exploration of localization and internationalization.

Industry insiders pointed out that this move not only breaks the time barrier of traditional capital operation methods, reduces the financial friction costs generated by corporate acquisitions, and realizes the connection between resource integration and capital upgrading, but also effectively guarantees the rights and interests of shareholders, providing a reference example for industrial integration and international development. It is also a vivid manifestation of actively responding to the country's decision-making and deployment of "optimizing the capital market structure."

In his public speech at the listing ceremony, Zhang Yingjun, Chairman of HEC Pharmaceutical, stated that with the success of this integration, the company will accelerate the integration of high-quality resources, rapidly promote the commercialization and globalization of its innovative drug pipeline, inject strong momentum into sustainable growth, and further enhance its core competitiveness in the global pharmaceutical market.

Public information shows that East Sunshine Pharmaceutical is a comprehensive pharmaceutical company engaged in drug research and development, production and commercialization. Since its establishment in 2003, with the mission of "improving the quality of human life and health through scientific research", it has always adhered to the innovation-driven and internationalization strategy, focusing on the three major fields of infection, chronic disease and tumor. It has a research and development team of more than 1,100 people, and its research and development strength ranks first in the domestic first echelon. It has 150 approved drugs worldwide and nearly 50 innovative drugs under development , of which 3 original new drugs have been approved for marketing, 1 is about to be launched, and 10 are in clinical phase II and III. Many pipelines have "First in class" or "Bestin class" potential; it has independently applied for more than 2,500 invention patents and obtained many high-level outputs and honorary certifications such as the National Key Laboratory for the Research and Development of New Anti-infective Drugs, the China Patent Gold Award, and the Guangdong Provincial Science and Technology Progress First Prize; in recent years, internationalization has also ushered in major breakthroughs. The innovative drug HEC88473 will be authorized overseas in 2024, and insulin glargine has completed registration in the United States; in addition, the company has established a global sales network, and its core product Kewei has become a domestic anti-influenza drug .The number one brand of medicine.

Data shows that in the first half of this year, Hong Kong-listed pharmaceutical IPOs achieved breakthroughs in both number and total funds raised. As policies continue to deepen, a group of innovative Chinese pharmaceutical companies, such as HEC Pharmaceutical, are expected to gain a more prominent position in the global market.

https://finance.eastmoney.com/a/202508073478674817.html